Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
暂无分享,去创建一个
Jae Cheol Lee | J. Shih | Youngchul Kim | G. Chang | J. Hung | K. Davis | Aliki Taylor | S. Yoo | S. Lee | S. Nagar | Shengyong Yang | Young-chul Kim